OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer-Reference-Cited by-同舟云学术

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Published:2019-04 Issue:4 Volume:30 Page:558-566
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Robson M.E.^ORCID,Tung N.,Conte P.^ORCID,Im S.-A.,Senkus E.,Xu B.,Masuda N.,Delaloge S.,Li W.,Armstrong A.,Wu W.,Goessl C.,Runswick S.,Domchek S.M.

Funder

AstraZeneca

AstraZeneca and Merck & Co.

Inc.

NIH/NCI Cancer Center

Breast Cancer Research Foundation

Mudskipper Business Ltd

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz012/28408683/mdz012.pdf

Reference7 articles.

1. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years;Malone;Cancer Res,2006

2. Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry;Kurian;Cancer Epidemiol Biomarkers Prev,2009

3. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer;Couch;J Clin Oncol,2015

4. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation;Robson;N Engl J Med,2017

5. Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit?;Kummel;Ann Oncol,2017

Cited by 548 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review;Cancer Treatment Reviews;2024-11

2. Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study;Future Oncology;2024-09-12

3. High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers;Acta Oncologica;2024-09-10

4. BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs?;npj Breast Cancer;2024-09-05

5. Mutation Spectrum Comparison between Benign Breast Lesion Cohort, Unselected Cancer Cohort and High-Risk Breast Cancer Cohort;Cancers;2024-09-03